What Sagimet Biosciences Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 5 | 10 |
| Total trades | 9 | 19 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 19 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Kemble George | Director | Aug 14 | Open-market sale · S | −350,987 | $10.23 | −$3.59M | 62,161 |
| Kemble George | Director | Aug 14 | Exercise / conversion · M | +24,369 | $6.36 | +$155K | 413,148 |
| Kemble George | Director | Aug 14 | Exercise / conversion · M | +326,618 | $6.36 | +$2.08M | 388,779 |
| Kemble George | Director | Aug 11 | Open-market sale · S | −20,206 | $9.95 | −$201K | 62,161 |
| Kemble George | Director | Aug 11 | Exercise / conversion · M | +10,455 | $6.36 | +$66.5K | 82,367 |
| Kemble George | Director | Aug 11 | Exercise / conversion · M | +9,751 | $6.36 | +$62K | 71,912 |
| Kemble George | Director | Jul 20 | Open-market sale · S | −18,844 | $7.46 | −$141K | 62,161 |
| Happel David | President & CEO | Jul 20 | Open-market sale · S | −64,051 | $7.76 | −$497K | 741,570 |
| Rozek Elizabeth | Chief Legal & Admin. Officer | Jul 20 | Open-market sale · S | −10,545 | $7.76 | −$81.8K | 224,414 |
| Martins Eduardo Bruno | Chief Medical Officer | Feb 19 | Grant / award · A | +44,000 | — | — | 147,296 |
| Chauche Thierry | Chief Financial Officer | Feb 19 | Grant / award · A | +44,000 | — | — | 59,688 |
| Happel David | President & CEO | Feb 19 | Grant / award · A | +128,000 | — | — | 805,621 |
| Rozek Elizabeth | Chief Legal & Admin. Officer | Feb 19 | Grant / award · A | +44,000 | — | — | 234,959 |
| Martins Eduardo Bruno | Chief Medical Officer | Feb 10 | Open-market sale · S | −3,640 | $5.36 | −$19.5K | 103,296 |
| Rozek Elizabeth | Chief Legal & Admin. Officer | Feb 10 | Open-market sale · S | −2,622 | $5.36 | −$14.1K | 190,959 |
| Chauche Thierry | Chief Financial Officer | Feb 10 | Open-market sale · S | −1,312 | $5.36 | −$7.03K | 15,688 |
| Happel David | President & CEO | Feb 10 | Open-market sale · S | −12,101 | $5.36 | −$64.9K | 677,621 |
| Kemble George | Executive Chairman | Nov 20 | Open-market sale · S | −37,688 | $7.69 | −$290K | 81,005 |
| Rozek Elizabeth | Chief Legal & Admin. Officer | Nov 04 | Grant / award · A | +9,855 | — | — | 193,581 |
| Martins Eduardo Bruno | Chief Medical Officer | Jul 21 | Open-market sale · S | −8,277 | $9.13 | −$75.6K | 106,936 |
Loading...
